Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 86

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 86
---
ants requiring the Company to maintain, on a consolidated basis as of the last day of each month, a fixed charge coverage
ratio of at least 1.10 to 1.0.

Harrow
Access for All

In
September 2025, we announced Harrow Access For All (“HAFA”) to expand our proprietary patient access model from a single
product to encompass Harrow’s comprehensive ophthalmic portfolio of branded, authorized generics (AGx), and compounded ophthalmic
medications. Beginning in late 2025 and expanding into 2027, HAFA will provide a single, unified access point for prescribers and patients,
offering affordability, streamlined prescribing, and predictable access. The platform creates a simpler, more predictable path to treatment—supporting
better outcomes for patients and greater efficiency for physicians.

32

Acquisition
of Remaining Interests in Melt Pharmaceuticals, Inc. 

In
September 2025, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among us, Harrow Acquisition
Sub, Inc., a wholly owned subsidiary of Harrow, Melt Pharmaceuticals, Inc. (“Melt”), and D. Brad Osborne, as stockholder
representative. Under the terms of the Merger Agreement and related milestone payment agreement, the Company agreed to acquire the remaining
equity interests of Melt in exchange for an initial cash payment of approximately $4,300,000 at closing, and contingent consideration
consisting of cash and Company equity upon achievement of (i) U.S. Food and Drug Administration (“FDA”) approval of the MELT-300
product candidate, (ii) coding and reimbursement of the MELT-300 product candidate, and (iii) various one-time sales milestones, as follows:

    ●
    Upon
    FDA approval of MELT-300, the Company shall pay an aggregate amount in cash of approximately $87,200,000.

    ●
    Upon
    receipt of pass-through status awarded and J-Code (or any other similar designation) issued by the Center for Medicare & Medicaid
    Services for MELT-300 the Company shall issue an aggregate of approximately 1,112,000 shares of the Company’s common stock.

    ●
    Upon
    achievement of various annual net sales milestones ranging from $100,000,000 to $1,000,000,000 per year, the Company shall make one-time
    cash payments that